Rare Blood Disorders

Rare blood disorders are a group of rare genetic disorders where the blood does not clot properly. Existing therapies for blood disorders place a high burden on patients and caregivers, requiring infusions as often as multiple times each week over a patient’s lifetime.

 

At Sigilon, we recognize this burden and understand that living or caring for someone with a rare blood disorder is more than just an infusion. It’s a caregiver of a young child learning to recognize the signs of a bleed or an adult having trouble with venous access or having arthritis and limited joint mobility as the result of years of infusions and peaks and troughs of factor.

 

Our Shielded Living Therapeutics™ platform has the potential to provide durable, consistent delivery of blood clotting factors for people with rare blood disorders.

Clinical Trials

SIG-001 is a candidate product for patients with severe or moderately severe hemophilia A (Factor VIII level 2% or less).

Sigilon plans to initiate a Phase 1/2 study in patients with severe or moderately severe hemophilia A in 2020. The study will evaluate the safety, tolerability, and efficacy of SIG-001 in adult male patients with severe or moderately severe hemophilia A without inhibitors.

Patient Resources

North America
EU
International
Back to Patients & Caregiver Overview